TABLE 1.
Exosomal RNA biomarkers related to diagnosis and prognosis of OSCC.
| Biomolecules | Molecules | Origin | Findings | Ref(s) |
|---|---|---|---|---|
| OncomiRs | ||||
| miR-24-3p | OSCC patients | Elevate in salivary exosomes of OSCC patients (AUC = 0.738) | He et al. (2020a) | |
| miR-23a-3p | SCC-9 and CAL-27 | OSCC cells derived exosomes enriched than OSCC cells | Cai and Qiao (2019) | |
| miR-155, miR-21 | serum samples of OSCC patients | upregulated in exosomes derived from primary tumor cells from OSCC patients than paired normal cells | Chen and Huang (2021) | |
| miR-342-3p, miR-1246 | HOC313-LM | express high in exosomes and promote its motility | Sakha et al. (2016) | |
| miR-30a | OSCC patients | a positive relation between the expression in exosomes and tissues of OSCC patients (AUC = 0.812) | He et al. (2021b) | |
| miR-302b-3p, miR-517b-3p | Saliva of OSCC patients | only discovered in EVs from OSCC patients saliva but healthy controls | Gai et al. (2018) | |
| miR-512-3p, miR-412-3p | OSCC patients | increase in comparison with the paired | Gai et al. (2018) | |
| miR-210 | plasma of OSCC patients | express higher than normal samples with AUC of 0.9513 | Bigagli et al. (2021) | |
| miR-365 | SCC25, CAL27 | exist in OSCC cell lines and extracellular vesicles | Coon et al. (2020) | |
| miR-21 | SCC-9, CAL-27 | drive recipient cells toward EMT, advantageous for tumor migration and invasion | Li and Zhu (2016) | |
| TSmiRs | ||||
| miR-126 | serum exosomes of OSCC patients | suppress angiogenesis, lymphangiogenesis and tumorigenesis by targeting EGFL7 | Chen and Huang (2021) | |
| miR-101-3p | CAL27, SCC9, TCA8113 | suppress OSCC progression | Xie et al. (2019a) | |
| Others | ||||
| circ_0000199 | OSCC cells from human sample | elevate in OSCC patients, associated with TNM stage, tumor size, lymphatic metastasis | Luo et al. (2020) | |
| lncRNA HOTTIP | FaDu, CNE-2Z, Hep-2 | inhibit HNSCC proliferation through M1 polarization | Jiang et al. (2022) | |
| lncRNA ADAMTS9-AS | CAL-27, SCC-9 | interect with miRs to regulate EMT and AKT signalling pathway and suppresses tumor growth, invasion and metastasis | Zhou et al. (2021) | |
| lncRNA LBX1-AS1 | THP-1, SCC-4, CAL-27 | inhibit tumor progression by regulate downstream FOXO expression | Ai et al. (2021) | |
| lncRNA FLJ22447 | HSC-3 | ingested by stromal CAFs to upregulate Lnc-CAF in turn, and co-express with IL-3 to promote OSCC growth | Ding et al. (2018) | |